Abstract
Botulinum toxin (BoNT) is a neurotoxin that has been used for many years to help treat muscle spasms and dystonias. In more recent years, the drug has been evaluated for use in neuropathic and other pain disorders, including disorders related to trigeminal nerve pain, such as migraine headache and trigeminal neuralgia (TN). The mechanism of action of BoNT for these disorders is not fully understood and continues to be evaluated; however, studies continue to support the efficacy and safety of BoNT for treatment of these disorders.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Park J, Park HJ. Botulinum toxin for the treatment of neuropathic pain. Toxins. 2017;9:260. https://doi.org/10.3390/toxins9090260.
Botox. Package insert. Allergan; 2019.
Nugent M, Yusef YR, Meng J, Wang J, Dolly JO. A SNAP-25 cleaving chimera of botulinum neurotoxin /A and /E prevents TNFα-induced elevation of the activities of native TRP channels on early postnatal rat dorsal root ganglion neurons. Neuropharmacology. 2018;138:257–66.
Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101:366–70.
Dima L, Balan A, Moga MA, Dinu CG, Dimienescu OG, Varga I, et al. Botulinum toxin a valuable prophylactic agent for migraines and a possible future option for prevention of hormonal variations-triggered migraines. Toxins. 2019;11:465. https://doi.org/10.3390/toxins11080465.
Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silbertstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT I trial. Cephalalgia. 2010;30:793–803. https://doi.org/10.1177/0333102410364676.
Deiner HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for the treatment of chronic migraine:results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalagia. 2010;30:804–14. https://doi.org/10.1177/0333102410364677.
Shah S, Calderon MD, Wu WD, Grant J, Rinehart J. Onabotulinumtoxin A (Botox) for the prophylactic treatment of pediatric migraine:a retrospective longitudinal analysis. J Child Neurol. 2018;33:580–6.
Ali SS, Bragin I, Rende E, Mejico L, Werner KE. Further evidence that onabotulinum toxin is a viable treatment option for pediatric chronic migraine patients. Cureus. 2019;11:e4343. https://doi.org/10.7759/cureus.4343.
Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen Y, Xie NC, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia:results from a randomized, double-blind, placebo-controlled trial. Cephalagia. 2012;32:443–50. https://doi.org/10.1177/0333102412441721.
Zhang H, Lian Y, Ma Y, Chen Y, He C, Xie N, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia:observation of therapeutic effect from randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014;15:65. http://www.thejournalofheadacheandpain.com/content/15/1/65
Shehata HS, El-Tamawy MS, Shalaby NM, Ramzy G. Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? J Headache Pain. 2013;14:92. http://www.thejournalofheadacheandpain.com/content/14/1/92
Zuniga C, Piedimonte F, Diaz S, Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharamcol. 2013;36(5):146–50.
Morra ME, Elgebaly A, Elmaraezy A, Khalil AM, Altibi AM, Vu TLH, et al. Therapeutic efficacy and safety of botulinum toxin A therapy in trigeminal neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2016;17:63. https://doi.org/10.1186/s10194-016-0651-8.
Boru UT, Duman A, Boluk C, Duman SC, Tasdemir M. Botulinum toxin in the treatment of trigeminal neuralgia: 6-month follow-up. Medicine. 2017;96:e8133. https://doi.org/10.1097/MD.0000000000008133.
De la Torre Canales G, Poluha RL, Lora VM, Ferreira DMAO, Stuginski-Barbosa J, Bonjardim LR, et al. Botulinum toxin type A applications for masticatory myofascial pain and trigeminal neuralgia: what is the evidence regarding adverse events? Clin Oral Investig. 2019;23:3411–21.
Liu J, Xu YY, Zhang QL, Luo WF. Efficacy and safety of botulinum toxin type A in treating patients of advanced age with idiopathic trigeminal neuralgia. Pain Res Manag. 2018;2018:7365148. https://doi.org/10.1155/2018/7365148.
Bendtsen L, Zakrzewska JM, Abbott J, Braschinsky M, Di Stefano G, Donnet A, et al. European Academy of Neurology guideline in trigeminal neuralgia. Neurology. 2019;26:831–49. https://doi.org/10.1111/ene.13950.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Nemergut, G. (2021). Botox Injections. In: Abd-Elsayed, A. (eds) Trigeminal Nerve Pain. Springer, Cham. https://doi.org/10.1007/978-3-030-60687-9_13
Download citation
DOI: https://doi.org/10.1007/978-3-030-60687-9_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-60686-2
Online ISBN: 978-3-030-60687-9
eBook Packages: MedicineMedicine (R0)